NEW YORK, Nov. 1 - AxCell Biosciences has been awarded a US patent covering nine claims to the company's Cloning of Ligand Targets proteomics technology, AxCell said on Thursday.
“This technology permits the use of ligands … to discover new domains and ultimately new proteins that may be useful as drug targets,” John Rodwell, president and chief technical officer of AxCell, said in a statement.
The patent, numbered 6,309,820 and entitled “Polypeptides Having a Functional Domain of Interest and Methods of Identifying and Using Same,” deals with a technology that AxCell says can enable researchers to measure protein interactions “in an industrialized, high-throughput manner.”
The nine claims deal cover the methods by which AxCell “identified SH3 domain-containing proteins from human protein expression libraries,” the company said in the statement. According to Princeton, NJ-based AxCell, proteins with these domains “play a role” in cancer, cardiovascular disease, central nervous system disorders, diabetes, and inflammatory disease.